Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL003 Cell Injection in Transfusion-dependent β-thalassemia
NCT06280378Phase 2Recruiting
- Sponsor
- Kanglin Biotechnology
- Start
- Apr 2024
- Primary completion
- Nov 2027
- Modality
- Gene Editing, Small Molecules, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of KL003 in beta thalassemia, sponsored by Kanglin Biotechnology. Started Apr 2024; status: recruiting.
02
Drugs
KL003
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT06280378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06280378.